Legend Biotech
Legend Biotech's revenue rose 64.0% to $1.0 billion in fiscal 2025. Its operating margin was −13.3%, up from −49.3% a year earlier. Free cash flow was −$129 million. The diluted share count rose 0.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Income statement
Legend Biotech lost money in fiscal 2025: a net loss of $297 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 689 | 786 | 1,278 | 287 | 902 |
| Debt incl. finance leases | 120 | 261 | 281 | 301 | 319 |
| Net debt (negative means net cash) | −568 | −525 | −996 | 14 | −583 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.2x | 0.3x | 0.2x | 0.3x | 0.3x |
| Interest coverage | −451.4x | −40.3x | −24.2x | −14.3x | −6.4x |
| Current ratio | 4.1x | 3.7x | 6.9x | 4.6x | 2.0x |
| Quick ratio | 4.1x | 3.7x | 6.8x | 4.5x | 1.9x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 6 of 9 | 5 of 9 | 2 of 9 |
| Rule of 40 | −1.3% | 94.8% | 51.5% |
| Altman Z'' | — | — | — |
| Accruals ratio | −7.9% | −1.9% | −11.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 6 of 9 | 5 of 9 | 2 of 9 |
Compare
Put Legend Biotech side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Legend Biotech | FY25 | 64.0% | −13.3% | −12.5% | −14.6% | — | 2 | |
| Lakefront Biotherapeutics NV | FY25 | 303.5% | 26.5% | −24.4% | — | — | — | Compare |
| Novavax | FY25 | 64.7% | 40.3% | −22.3% | — | −1.0x | 5 | Compare |
| BioCryst Pharmaceuticals | FY25 | 94.1% | 39.0% | 39.4% | — | −0.8x | 7 | Compare |
| Harmony Biosciences | FY25 | 21.5% | 24.0% | 40.1% | 48.9% | — | 5 | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 49 | 60 | 75 | 69 | 117 | 285 | 627 | 1,029 |
| Revenue growth | — | 22.1% | 25.0% | −8.2% | 70.0% | 143.7% | 120.0% | 64.0% |
| Gross profit | — | — | 75 | 69 | 52 | 141 | 411 | 632 |
| Research and development | 61 | 162 | 232 | 313 | 336 | 382 | 414 | 415 |
| Operating income | — | — | — | — | — | −528 | −310 | −136 |
| Net income | −3 | −102 | −266 | −404 | −446 | −518 | −177 | −297 |
| Diluted EPS (US$) | −0.01 | −0.51 | −1.13 | −1.43 | −1.40 | −1.47 | −0.48 | −0.81 |
| Diluted shares (millions) | 200 | 200 | 236 | 282 | 318 | 352 | 366 | 369 |
| Cash flow | ||||||||
| Cash from operations | 308 | −83 | −223 | −198 | −201 | −393 | −144 | −100 |
| Capital expenditure | 21 | 27 | 26 | 42 | 21 | 20 | 14 | 29 |
| Free cash flow | 287 | −110 | −249 | −241 | −222 | −413 | −158 | −129 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 1 | 5 | 20 | 34 | 48 | 69 | 65 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 210 | 83 | 456 | 689 | 786 | 1,278 | 287 | 902 |
| Debt incl. finance leases | — | — | — | 120 | 261 | 281 | 301 | 319 |
| Total assets | — | 288 | 722 | 1,120 | 1,331 | 1,849 | 1,670 | 1,734 |
| Total liabilities | — | 411 | 124 | 354 | 587 | 597 | 630 | 732 |
| Shareholders' equity | 253 | −123 | 598 | 766 | 744 | 1,251 | 1,040 | 1,002 |
| Margins and ratios | ||||||||
| Gross margin | — | — | 100.0% | 100.0% | 44.1% | 49.4% | 65.5% | 61.4% |
| Operating margin | — | — | — | — | — | −185.2% | −49.3% | −13.3% |
| Net margin | −5.7% | −169.4% | −355.2% | −586.4% | −381.5% | −181.8% | −28.2% | −28.9% |
| Free cash flow margin | 583.6% | −183.1% | −332.4% | −349.7% | −189.9% | −145.0% | −25.2% | −12.5% |
| Rule of 40 (growth + FCF margin) | — | −161.1% | −307.3% | −357.9% | −119.9% | −1.3% | 94.8% | 51.5% |
| Return on capital | — | — | — | — | −164.9% | −175.9% | −37.3% | −14.6% |
| Return on equity | — | — | −112.2% | −59.2% | −59.1% | −51.9% | −15.4% | −29.1% |
| Return on assets | — | — | −52.8% | −43.8% | −36.4% | −32.6% | −10.1% | −17.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |